SCHEDULE 13G/A 0001193125-22-018295 0001591046 XXXXXXXX LIVE 1 Class A Common Stock, $0.0001 par value per share 12/31/2024 0001637715 OnKure Therapeutics, Inc. 68277Q105 6707 Winchester Circle, #400 Boulder CO 80301 Rule 13d-1(d) Lundbeckfond Invest A/S b G7 203122.00 0.00 203122.00 0.00 203122.00 1.6 FI Lene Skole b G7 203122.00 0.00 203122.00 0.00 203122.00 1.6 IN OnKure Therapeutics, Inc. 6707 Winchester Circle, #400, Boulder, CO, 80301. This joint statement on Schedule 13G is being filed by Lundbeckfond Invest A/S ("Lundbeckfond") and Lene Skole ("Skole"). Lundbeckfond and Skole collectively are referred to as the "Reporting Persons." The principal business office of each Reporting Person is: c/o Lundbeckfond Invest A/S, Scherfigsvej 7, DK-2100, Copenhagen, Denmark. Lundbeckfond is a private Danish corporation. Skole is a citizen of Denmark. Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of 203,122 shares of Class A Common Stock held by Lundbeckfond. Skole is the Chief Executive Officer of Lundbeckfond and may be deemed to have sole power to vote and dispose of these shares. The directors of Lundbeckfond have delegated voting and dispositive power with respect to the shares held by Lundbeckfond to Skole. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference. The percentage set forth in Row 11 of each Reporting Person's cover page is based upon 12,652,890 shares of the Issuer's Class A Common Stock outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 7, 2024. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference. N Y Y Y Y Y Y Exhibit 99.1 Joint Filing Agreement, dated January 26, 2022, among the Reporting Persons (incorporated by reference to Exhibit 1 to Schedule 13G filed on January 26, 2022) Lundbeckfond Invest A/S /s/ Lene Skole 02/06/2025 /s/ Christian Elling 02/06/2025 Lene Skole /s/ Lene Skole 02/06/2025